miR-142-3p Regulates BDNF Expression in Activated Rodent Microglia Through Its Target CAMK2A

Neelima Gupta1, Shweta Jadhav1, Kai-Leng Tan1

  • 1Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Insights

Microglial miR-142-3p regulates the CAMK2A-CREB-BDNF pathway, impacting synaptic plasticity. This study identifies key microRNAs in activated microglia and their role in neuroinflammation and learning mechanisms.

Area of Science:

  • Neuroscience
  • Immunology
  • Epigenetics

Background:

  • Microglia are key immune cells in the central nervous system (CNS), crucial for its development, homeostasis, and response to injury.
  • Epigenetic mechanisms, including microRNAs (miRNAs), regulate microglial activation and function.
  • Microglial activation is vital for CNS protection but can contribute to pathology.

Purpose of the Study:

  • To identify differentially expressed miRNAs in activated primary microglia.
  • To investigate the role of miR-142-3p in regulating the CAMK2A-BDNF pathway in activated microglia.
  • To understand the impact of this pathway on synaptic plasticity.

Main Methods:

  • MicroRNA microarray analysis of lipopolysaccharide (LPS)-activated primary microglia.
  • Luciferase reporter assays to confirm miRNA-target interactions.
  • Overexpression and knockdown studies (shRNA) to assess functional effects on gene expression and protein levels.

Main Results:

  • miR-142-3p was significantly upregulated in LPS-activated microglia.
  • miR-142-3p directly targets and downregulates CAMK2A expression in microglia.
  • Downregulation of CAMK2A by miR-142-3p leads to decreased BDNF expression via CREB phosphorylation, impacting synaptic plasticity.

Conclusions:

  • This study provides a comprehensive miRNA profile of activated microglia.
  • Microglial miR-142-3p is a key regulator of the CAMK2A-CREB-BDNF signaling pathway.
  • The miR-142-3p/CAMK2A/BDNF axis in microglia influences synaptic plasticity, offering potential therapeutic targets.